A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
Latest Information Update: 17 Apr 2019
At a glance
- Drugs Poliovirus vaccine inactivated Intravacc/Sinovac/WHO (Primary)
- Indications Poliomyelitis
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
- 16 Apr 2019 Results presented in the Sinovac Biotech media release.
- 08 Apr 2019 Primary endpoint has been met. (The seroconversion rates (SCRs) of each group after primary immunization.) published in the Journal of Infectious Diseases.
- 08 Apr 2019 Results assessing sIPV demonstrating an immunogenicity profile noninferior to that of the conventional IPV, also as a good safety profile published in the Journal of Infectious Diseases